Glioma progression and molecular characteristics (e.g., IDH mutations or mesenchymal gene signature) have distinct effects on major immune cell subsets, and conversely, different proportions of immune cell subsets and their polarization or activation states may have different effects on tumor progression, response to therapy, and survival. This evidence concerns the gene IDH1 and central nervous system cancer.